Amicus Therapeutics, Inc. (FOLD) stock saw a modest uptick, ending the day at $9.41 which represents a slight increase of $0.05 or 0.53% from the prior close of $9.36. The stock opened at $9.46 and ...

Cantor Fitzgerald reiterated their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $21.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on FOLD stock, giving a Buy rating on January 13.Stay Ahead of ...

Analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report) and keeping the price target at $20.00.Stay Ahead ...

Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected ...

Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and ...

Amicus Therapeutics, Inc. (FOLD) stock saw a decline, ending the day at $9.02 which represents a decrease of $-0.44 or -4.65% from the prior close of $9.46. The stock opened at $9.34 and touched a low ...

If you’re on the fence about investing in Amicus Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors ...

PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43 rd Annual J.P ...